Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
Public ClinicalTrials.gov record NCT00640419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of 0.7 mg/kg/Day and 1.4 mg/kg/Day of ABT-089 in the Treatment of Children With Attention Deficit-Hyperactivity Disorder (ADHD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention Deficit Hyperactivity Disorder (ADHD).
Study identification
- NCT ID
- NCT00640419
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 121 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 12 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Jul 2008 (Actual)
- Completion
- Jul 2008 (Actual)
- Last update posted
- Jan 18, 2013
2008
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 7536 | Little Rock | Arkansas | 72205 | — |
| Site Reference ID/Investigator# 7954 | Bradenton | Florida | 34208 | — |
| Site Reference ID/Investigator# 7543 | Jacksonville | Florida | 32216 | — |
| Site Reference ID/Investigator# 7542 | Orlando | Florida | 32806 | — |
| Site Reference ID/Investigator# 7537 | Libertyville | Illinois | 60048 | — |
| Site Reference ID/Investigator# 7561 | Overland Park | Kansas | 66212 | — |
| Site Reference ID/Investigator# 7560 | Troy | Michigan | 48085 | — |
| Site Reference ID/Investigator# 7559 | Omaha | Nebraska | 68198 | — |
| Site Reference ID/Investigator# 7541 | Las Vegas | Nevada | 89128 | — |
| Site Reference ID/Investigator# 7564 | Oklahoma City | Oklahoma | 73103 | — |
| Site Reference ID/Investigator# 7538 | Portland | Oregon | 97210 | — |
| Site Reference ID/Investigator# 7540 | Memphis | Tennessee | 38119 | — |
| Site Reference ID/Investigator# 7544 | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00640419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2013 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00640419 live on ClinicalTrials.gov.